Results 261 to 270 of about 75,992 (272)

<p>Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients</p>

Therapeutics and Clinical Risk Management, 2019
Haijun Zhang
exaly  

Neoadjuvant ipilimumab–nivolumab superior to adjuvant nivolumab

Nature Reviews Clinical Oncology
openaire   +2 more sources

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

Neuro-Oncology, 2018
GORDANA Vlahovic, Michael Lim, Joachim M Baehring   +2 more
exaly  

Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types

Annals of Oncology, 2020
exaly  

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of Thoracic Oncology, 2018
Scott Gettinger, Matthew D Hellmann, Jonathan W Goldman   +2 more
exaly  

Nivolumab

Reactions Weekly, 2022
openaire   +1 more source

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Journal of Thoracic Oncology, 2018
Hidetoshi Hayashi, Yasutaka Chiba, Keita Kudo   +2 more
exaly  

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial

Lancet, The
JOSÉ LUIS MANZANO Mozo, Eray Goekkurt, Francine Aubin   +2 more
exaly  

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

European Urology, 2017
Bernard Escudier, Robert J Motzer, John Wagstaff   +2 more
exaly  

Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective

Annals of Oncology, 2019
exaly